Michael S. Chang, M., Jordan T. Said, M., Elliot H. Akama-Garren, P., Nicole Trepanowski, M., Ai-Tram N. Bui, M., Anita Giobbie-Hurder, M., . . . Rebecca I. Hartman, M. (2025). NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors. JAAD International, 18(165-167), 165. https://doi.org/10.1016/j.jdin.2024.11.004
Chicago-referens (17:e uppl.)Michael S. Chang, MD, MD Jordan T. Said, PhD Elliot H. Akama-Garren, MD Nicole Trepanowski, MD Ai-Tram N. Bui, MS Anita Giobbie-Hurder, MD Nicole R. LeBoeuf, och MD Rebecca I. Hartman. "NRAS Tumor Mutations Are Associated with Reduced Odds of Dermatologic Adverse Events in Patients with Metastatic Melanoma Receiving Immune Checkpoint Inhibitors." JAAD International 18, no. 165-167 (2025): 165. https://doi.org/10.1016/j.jdin.2024.11.004.
MLA-referens (9:e uppl.)Michael S. Chang, MD, et al. "NRAS Tumor Mutations Are Associated with Reduced Odds of Dermatologic Adverse Events in Patients with Metastatic Melanoma Receiving Immune Checkpoint Inhibitors." JAAD International, vol. 18, no. 165-167, 2025, p. 165, https://doi.org/10.1016/j.jdin.2024.11.004.
